Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.5
4.8
Journals
Antibiotics
Special Issues
Antibiotic Therapy for Critically Ill Patients in the Age of...
share announcement

Antibiotic Therapy for Critically Ill Patients in the Age of COVID-19

A special issue of Antibiotics (ISSN 2079-6382).

Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 2908

Special Issue Editors

Dr. Giancarlo Ceccarelli

E-Mail Website
Guest Editor
Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy
Interests: hospital acquired infections; MDR infections; STD; special populations and migrants
Special Issues, Collections and Topics in MDPI journals
Dr. Francesco Alessandri

E-Mail Website
Guest Editor
Assistant Professor, Department of Anesthesia, Critical Care and Pain Medicine, Sapienza University of Rome, Rome, Italy
Interests: critical care medicine; intensive care medicine; sepsis; pneumonia; extracorporeal techniques; infections in ICU
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Treatment guidelines for community-acquired pneumonia recommend initial empiric antibiotic therapy for possible bacterial infection or co-infection, given that they often coexist and there are no clear diagnostic tests for determining if the pneumonia is solely due to a virus at the time of onset. On the other hand, treatment decisions must be weighed taking into account the rise of multidrug-resistant bacteria and complications associated with antibiotic use. Currently, there are no clear estimates on the incidence of bacterial co-infection in patients with COVID-19 and no clinical trials have been conducted on the use of empiric antibiotics in these patients. Some macrolides, teicoplanin and fluoroquinolones have been analyzed for their potential capacity to bind to SARS-CoV-2. We aimed to evaluate original articles and reviews to improve the knowledge on this interesting topic.

Dr. Giancarlo Ceccarelli
Dr. Francesco Alessandri
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antibiotic therapy
  • antibiotic resistance
  • COVID-19

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 977 KiB  
Article
Clinical Impact of COVID-19 on Multi-Drug-Resistant Gram-Negative Bacilli Bloodstream Infections in an Intensive Care Unit Setting: Two Pandemics Compared
by Francesco Cogliati Dezza, Gabriele Arcari, Federica Alessi, Serena Valeri, Ambrogio Curtolo, Federica Sacco, Giancarlo Ceccarelli, Giammarco Raponi, Francesco Alessandri, Claudio Maria Mastroianni, Mario Venditti and Alessandra Oliva
Antibiotics 2022, 11(7), 926; https://doi.org/10.3390/antibiotics11070926 - 09 Jul 2022
Cited by 18 | Viewed by 2487
Abstract
Two mutually related pandemics are ongoing worldwide: the COVID-19 and antimicrobial resistance pandemics. This study aims to evaluate the impact of COVID-19 on multi-drug-resistant Gram-negative bacteria (MDR-GN) bloodstream infections (BSIs) in a single intensive care unit (ICU). We conducted a retrospective study including [...] Read more.
Two mutually related pandemics are ongoing worldwide: the COVID-19 and antimicrobial resistance pandemics. This study aims to evaluate the impact of COVID-19 on multi-drug-resistant Gram-negative bacteria (MDR-GN) bloodstream infections (BSIs) in a single intensive care unit (ICU). We conducted a retrospective study including patients admitted to the ICU, reorganized for COVID-19 patients’ healthcare, with at least one confirmed MDR-GN BSI during 2019–2020. We compared clinical and microbiological features, incidence density, antibiotic therapy and mortality rate in pre- and during-COVID-19 pandemic periods. We estimated the impact of COVID-19 on mortality by means of univariate Cox regression analyses. A total of 46 patients were included in the study (28 non-COVID-19/18 COVID-19). Overall, 63 BSI episodes occurred (44/19), and non-COVID-19 patients had a higher incidence of MDR-GN BSIs and were more likely to present K. pneumoniae BSIs, while the COVID-19 group showed more A. baumannii BSIs with higher per pathogen incidence. COVID-19 patients presented more critical conditions at the BSI onset, a shorter hospitalization time from BSI to death and higher 30-day mortality rate from BSI onset. COVID-19 and septic shock were associated with 30-day mortality from MDR-GN BSIs, while early active therapy was a protective factor. In conclusion, COVID-19 showed a negative impact on patients with MDR-GN BSIs admitted to the ICU. Full article
(This article belongs to the Special Issue Antibiotic Therapy for Critically Ill Patients in the Age of COVID-19)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop